A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.
Fiche publication
Date publication
janvier 2018
Journal
Journal of thoracic disease
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle
Tous les auteurs :
Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA
Lien Pubmed
Résumé
Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition.
Mots clés
Brain metastases, bevacizumab, non-small cell lung cancer (NSCLC), pemetrexed
Référence
J Thorac Dis. 2018 Jan;10(1):219-227